ABAlexa Badalamenti

Alexa Badalamenti

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Alexa Badalamenti has a total of 18 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Electronic Patient Portals as a Modality for Returning Reclassified Genetic Test Results

    by Sukh Makhnoon, MinJae Lee, Mujeeb Basit, Cindy Kao, Sun Won Min, Christine Mai, Alexa Badalamenti, Jacqueline Mersch

    Background: Most reclassified genetic test results are clinically inactionable and burdensome for healthcare providers to return to patients. The feasibility of using electronic patient portals (e.g., MyChart) to return reclassified results remains unclear.Methods: Patient and provider initiated MyChart actions were obtained from MyChart data and matched to patient demographic and clinical information using unique patient medical record numbers. Data on who (patient or provider) sent and read these messages and when (date and time) were collected for clinically actionable and inactionable reclassifications.Results: Among 801 patients with 828 reclassified variants in cancer susceptibility genes, 551 had an active MyChart account at the time of reclassification. Patients with active MyChart accounts were less likely to be Hispanic (p < 0.001) compared to other ethnic groups. Of these, 302 (55%) were notified about 308 reclassified results (307 inactionable and 1 actionable) via MyChart messages, and 80% (244/302) read the message within a median time of 3.6 h.Conclusion: We find that it is feasible to return reclassified results via electronic patient portals for most patients, but alternative modalities are still necessary. Unidirectional, low‐touch modalities of recontact can be used to efficiently return the increasing number of inactionable reclassified results.


  • Exploring the role of germline genetic testing in surgical decision making for early-stage invasive breast cancer: insights from a safety-net hospital

    by Vineeth Kommidi, Manasa Kotamraju, Keerthana Chakka, Sharlene Dong, Alexa Badalamenti, Caitlin Mauer Hall, Ashley Quinn, Emily Goff, Chul Ahn, Ang Gao, et al.

    Current guidelines recommend contralateral prophylactic mastectomy (CPM) for women with unilateral breast cancer who have pathogenic/likely pathogenic variants (PV) in high-risk genes, but not for those with variants of uncertain significance (VUS). However, VUS results can cause significant psychosocial distress, which may influence surgical decision-making. In safety-net settings, concerns about insurance coverage and additional social determinants of health may further impact CPM decisions. This study examines surgical trends among patients with early-stage invasive breast cancer who underwent genetic testing before surgery at a safety-net hospital in Dallas, Texas between 2012–2022. We performed a retrospective chart review of 300 early-stage breast cancer patients referred for genetic counseling, analyzing demographics, tumor characteristics, genetic testing results, and treatment. Descriptive statistics and regression analyses were performed. The cohort included 116 patients without mutations (control), 111 with VUS, and 73 with PV. 86.30% of PV patients, 30.63% of VUS patients, and 18.10% of the control group underwent CPM. Multivariate analysis identified PV (OR 26.35, 95% CI: 10.97–63.29, p < 0.0001), VUS (OR 2.35, 95% CI: 1.16–4.77, p = 0.0175), and age at diagnosis (OR 0.963, 95% CI: 0.934–0.993, p = 0.0168) as independent predictors of CPM. These findings suggest that factors beyond established guidelines may influence surgical decision-making, particularly for patients in safety-net hospital settings, underscoring the need for thorough provider and patient counseling.